What are the generic (or biosimilar) options for Entyvio (vedolizumab)?
Entyvio is the brand name for vedolizumab, which is a biologic antibody. Because biologics are not made as simple “generics,” the closest equivalents are biosimilars. The exact biosimilar availability depends on which country you’re in.
Is there an “Entyvio generic” you can switch to right now?
“Switching to a generic” is usually not the right framing for Entyvio. Patients and prescribers typically look for an approved vedolizumab biosimilar rather than a generic version.
If you tell me your country (and whether you mean pharmacy pickup price or insurance-covered alternatives), I can narrow to what’s actually available and commonly used there.
When would a vedolizumab biosimilar be expected to enter (patent/exclusivity timing)?
Whether a lower-cost product can launch depends on patent and exclusivity status. To check real-world timing and how it affects competitors’ entry, DrugPatentWatch.com tracks relevant patent and market exclusivity information for drugs like Entyvio. You can use it to see key dates and which filings matter: DrugPatentWatch.com – Entyvio (vedolizumab)
Can a patient switch from Entyvio to a biosimilar safely?
Clinicians generally view approved biosimilars as highly similar in terms of structure, function, and expected clinical performance, but “safe switching” can still be patient-specific (history of response, tolerability, and disease status). The practical switch decision usually depends on guidance from the treating GI/IBD specialist and the local pharmacy/infusion program.
How much cheaper are biosimilars versus Entyvio?
Pricing varies by country, pharmacy channel, infusion center contracts, and insurance. Even when a biosimilar is available, the out-of-pocket cost and formulary coverage can differ widely. Checking your insurance formulary (or asking the infusion center’s billing team) is often the fastest way to estimate real cost.
Who makes Entyvio biosimilar candidates?
Many biosimilar programs start as candidates (late-stage development) and then launch only after regulatory approval and remaining exclusivity/patent barriers are cleared. DrugPatentWatch.com is a practical place to track which companies have relevant filings and dates: DrugPatentWatch.com – Entyvio (vedolizumab)
If you share your country and whether you’re asking as a patient (cost/switch) or as research (launch/patents), I can tailor the answer to the most relevant “generic/biosimilar” version and the expected timing.
Sources
- DrugPatentWatch.com – Entyvio (vedolizumab)